Acronyms frequently used in multiple myeloma

Sometimes, you will hear or read unfamiliar medical terms that make it harder to understand multiple myeloma. If your care team is using words you don't understand, it is ok to tell them that you don't understand the words they are using and ask them to explain it in a different way.

ACT	Adaptive Cell Transfer
ADC	Antibody drug conjugate
Allo	Allogeneic Stem Cell Transplant
ASCO	American Society of Clinical Oncology
ASCT	Autologous Stem Cell Transplant
ASH	American Society of Hematology
Auto	Autologous Stem Cell Transplant
BCMA	B-cell maturation antigen
BiTE	Bispecific T-cell Engager
BMA	Bone Marrow Aspirate or Bone Modifying Agent
BMB	Bone Marrow Biopsy
BMT	Bone Marrow Transplant
BORT	Bortezomib
BP	Bisphosphonate
CAR	Chimeric antigen receptors
CAR-T	A form of immunotherapy that uses specially altered T-cells
CBC	Complete Blood Count
CBD	Cannbidiol one of 113 cannbinoids in cannabis
CD	In cells, refers to Cluster of Differentation
CD138	A protein expressed on plasma cells especially MM cells used as a marker
CD34	A protein marker of hematopoietic stem cells
CD38	A protein marker of cell activation on myeloma cells
CR	Complete Response
Cr	Creatinine
CRAB	CRAB Calcium Renal Anemia Bone Disease
CRP C	C-Reactive Protein
CRS	Cytokine Release Syndrome
CT	Computerized Tomography Scan (3D X-ray)
Cy	Cyclophosphamide
CyBorD	Cyclophosphamide, Velcade (Bortezomib), Dexamethasone
Dara	Daratumumab (Darzalex)
DCEP	Dexamethasone, Cyclophosphamide, Etoposide and Cisplatin
DEX	Dexamethasone
DKd	Daratumumab, carfilzomib, dexamethasone
DLC	Digital Life Coaching
DLT	Dose-limiting toxicity
DPACE	Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide
DOR	Duration of Response
DRd	Daratumumab, Revlimid, low-dose Dexamethasone
DVD	Doxil, Vincristine, Dexamethasone
DVT	Deep Vein Thrombosis
EFS	Event Free Survival
EHR	Electronic health record
EMD	Extramedullary Disease (myeloma outside the bone marrow) marrow)
EOB	Explanation of benefits
ERD	Elotuzumab (Empliciti), Revlimid, Dexamethasone
FDA	Federal Drug Administration
FISH	Fluorescent In Situ Hybridization
FLC	Free Light Chain
GEP	Gene Expression Profile
GSI	Gamma Secretase Inhibitor
GVHD	Graft Versus Host Disease
HDAC	Histone Deacetylase
HDT	High-Dose Therapy
HIPAA	Health Insurance Poratability and Accountability Act
HRQoL	Health related Quality of Life
HRSMM	High-Risk Smoldering Multiple Myeloma
HSC	Hematopoietic stem cells
HTU	Healthtree University
I	Ixazomib (Ninlaro)
IEP	Immunoelectrophoresis
IFE	Immunofixation Electrophoresis
Ig	Immunoglobulin
IM	Intramuscular (shot or injection into the muscle)
IMF	International Myeloma Foundation
IMiD	Oral immunomodulatory agent
IRD	Ixazomib (Ninlaro), Revlimid, Dexamethasone
ISS	International Staging System
IV	Intravenous (injection into the vein)
IVIG	Intravenous Immunoglobulin
K	Kyprolis (Carfilzomib)
Kd	Carfilzomib, dexamethasone
KRD	Kyprolis (Carfilzomib), Revlimid, Dexamethasone
Len	Lenadidomide
LoD	Limit of Detection (MRD testing)
LOT	Lines of Therapy
LLS	Leukemia & Lymphoma Society
MAB	Monoclonal Antibodies
M-protein or spike	Monoclonal protein
MDE	Myeloma Defining Event
MEL 200	Dose of melphalan administered in ASCT: 200 mg of melphalan per square meter of body mass
MGUS	Monoclonal Gammopathy of Undetermined Significance
MMRF	Multiple Myeloma Research Foundation
MP	Melphalan & Prednisone
MPR	Melphalan, Prednisone, Revlimid
MPT	Melphalan, Prednisone, Thalidomide
MR	Minimal Response (between 25% and 50% response)
MRD	Minimal Residual Disease
MRD Neg	Absence of tumor plasma cell within 1,000,000 bone marrow cells
MRI	Magnetic Resonance Imaging
MTD	Maximum Tolerated Dose
NA or N/A	Not Available
nCR	Near-Complete Response
NDMM	Newly Diagnosed Multiple Myeloma
NGF	Next-Generation Flow (new 8-color flow cytometry test)
NGS	Next-Generation Sequencing (new DNA-sequencing test)
NK	Natural Killer (cell)
NR	Not Reached
ONJ	Osteonecrosis of the Jaw
ORR	Overall Response Rate
OS	Overall survival
PBSCT	Peripheral Blood Stem Cell Transplant
PCLI	Plasma Cell Labeling Index
PDC	Peptide-drug conjugate
PET	Positron Emission Tomography
PET/CT	PET combined with a CT scan
PFS	Progression-Free Survival
PI	Protenase Inhibitor
PN	Peripheral Neuropathy
POM	Pomalidomide (Pomalyst®)
PR	Partial Response
PSCT	Peripheral Stem Cell Transplant
QoL	Quality of Life
RBC	Red Blood Cells
REVLoDEX	Revlimid, low-dose Dexamethasone
RMPT	Revlimid, Melphalan, Prednisone, Thalidomide
RRMM	Relapsed/Refractory Multiple Myeloma
RVd	Revlimid, Velcade, low-dose Dexamethasone
RVD	Revlimid, Velcade, Dexamethasone
RWD	Real world data
sCR	Stringent Complete Response (CR plus normal free light chain ratio and no clonal plasma cells)
SCT	Stem Cell Transplant
SD	Stable Disease
SINE	Selective Inhibitor of Nuclear Export (Selinexor)
SMM	Smoldering Multiple Myeloma
SPEP	Serum Protein Electrophoresis
SPM	Second Primary Malignancy
SQ	Subcutaneous (sometimes abbreviated SC)
SRE	Skeletal Related Event
ß2M	Beta-2 Microglobulin
TCR	T-cell Receptor
TMI	Too Much Information
TTP	Time to Progression
UHiR	Ultra-High Risk
UPEP	Urine Protein Electrophoresis
VCF	Vertebral Compression Fracture
VDT-PACE	Velcade, Dexamethasone, Thalidomide, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide
VEGF	Vascular Endothelial Growth Factor
VGPR	Very Good Partial Response
VMP-Dara	Velcade, Melphalan, Prednisone plus Daratumumab (RRMM)
VRd	Velcade, Revlimid, Low-Dose Dexamethasone
VTD	Velcade, Thalidomide, Dexamethasone
VTD-Dara	Velcade, Thalidomide, Dexamethasone, Daratumumab
WBC	White Blood Cells
WBLD CT	Whole-Body Low-Dose CT
WBLD MRI	Whole-Body Low-Dose MRI
ZOL	Zoledronic acid (Zometa)

ACT	Adaptive Cell Transfer
ADC	Antibody drug conjugate
Allo	Allogeneic Stem Cell Transplant
ASCO	American Society of Clinical Oncology
ASCT	Autologous Stem Cell Transplant
ASH	American Society of Hematology
Auto	Autologous Stem Cell Transplant
BCMA	B-cell maturation antigen
BiTE	Bispecific T-cell Engager
BMA	Bone Marrow Aspirate or Bone Modifying Agent
BMB	Bone Marrow Biopsy
BMT	Bone Marrow Transplant
BORT	Bortezomib
BP	Bisphosphonate
CAR	Chimeric antigen receptors
CAR-T	A form of immunotherapy that uses specially altered T-cells
CBC	Complete Blood Count
CBD	Cannbidiol one of 113 cannbinoids in cannabis
CD	In cells, refers to Cluster of Differentation
CD138	A protein expressed on plasma cells especially MM cells used as a marker
CD34	A protein marker of hematopoietic stem cells
CD38	A protein marker of cell activation on myeloma cells
CR	Complete Response
Cr	Creatinine
CRAB	CRAB Calcium Renal Anemia Bone Disease
CRP C	C-Reactive Protein
CRS	Cytokine Release Syndrome
CT	Computerized Tomography Scan (3D X-ray)
Cy	Cyclophosphamide
CyBorD	Cyclophosphamide, Velcade (Bortezomib), Dexamethasone
Dara	Daratumumab (Darzalex)
DCEP	Dexamethasone, Cyclophosphamide, Etoposide and Cisplatin
DEX	Dexamethasone
DKd	Daratumumab, carfilzomib, dexamethasone
DLC	Digital Life Coaching
DLT	Dose-limiting toxicity
DPACE	Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide
DOR	Duration of Response
DRd	Daratumumab, Revlimid, low-dose Dexamethasone
DVD	Doxil, Vincristine, Dexamethasone
DVT	Deep Vein Thrombosis
EFS	Event Free Survival
EHR	Electronic health record
EMD	Extramedullary Disease (myeloma outside the bone marrow) marrow)
EOB	Explanation of benefits
ERD	Elotuzumab (Empliciti), Revlimid, Dexamethasone
FDA	Federal Drug Administration
FISH	Fluorescent In Situ Hybridization
FLC	Free Light Chain
GEP	Gene Expression Profile
GSI	Gamma Secretase Inhibitor
GVHD	Graft Versus Host Disease
HDAC	Histone Deacetylase
HDT	High-Dose Therapy
HIPAA	Health Insurance Poratability and Accountability Act
HRQoL	Health related Quality of Life
HRSMM	High-Risk Smoldering Multiple Myeloma
HSC	Hematopoietic stem cells
HTU	Healthtree University
I	Ixazomib (Ninlaro)
IEP	Immunoelectrophoresis
IFE	Immunofixation Electrophoresis
Ig	Immunoglobulin
IM	Intramuscular (shot or injection into the muscle)
IMF	International Myeloma Foundation
IMiD	Oral immunomodulatory agent
IRD	Ixazomib (Ninlaro), Revlimid, Dexamethasone
ISS	International Staging System
IV	Intravenous (injection into the vein)
IVIG	Intravenous Immunoglobulin
K	Kyprolis (Carfilzomib)
Kd	Carfilzomib, dexamethasone
KRD	Kyprolis (Carfilzomib), Revlimid, Dexamethasone
Len	Lenadidomide
LoD	Limit of Detection (MRD testing)
LOT	Lines of Therapy
LLS	Leukemia & Lymphoma Society
MAB	Monoclonal Antibodies
M-protein or spike	Monoclonal protein
MDE	Myeloma Defining Event
MEL 200	Dose of melphalan administered in ASCT: 200 mg of melphalan per square meter of body mass
MGUS	Monoclonal Gammopathy of Undetermined Significance
MMRF	Multiple Myeloma Research Foundation
MP	Melphalan & Prednisone
MPR	Melphalan, Prednisone, Revlimid
MPT	Melphalan, Prednisone, Thalidomide
MR	Minimal Response (between 25% and 50% response)
MRD	Minimal Residual Disease
MRD Neg	Absence of tumor plasma cell within 1,000,000 bone marrow cells
MRI	Magnetic Resonance Imaging
MTD	Maximum Tolerated Dose
NA or N/A	Not Available
nCR	Near-Complete Response
NDMM	Newly Diagnosed Multiple Myeloma
NGF	Next-Generation Flow (new 8-color flow cytometry test)
NGS	Next-Generation Sequencing (new DNA-sequencing test)
NK	Natural Killer (cell)
NR	Not Reached
ONJ	Osteonecrosis of the Jaw
ORR	Overall Response Rate
OS	Overall survival
PBSCT	Peripheral Blood Stem Cell Transplant
PCLI	Plasma Cell Labeling Index
PDC	Peptide-drug conjugate
PET	Positron Emission Tomography
PET/CT	PET combined with a CT scan
PFS	Progression-Free Survival
PI	Protenase Inhibitor
PN	Peripheral Neuropathy
POM	Pomalidomide (Pomalyst®)
PR	Partial Response
PSCT	Peripheral Stem Cell Transplant
QoL	Quality of Life
RBC	Red Blood Cells
REVLoDEX	Revlimid, low-dose Dexamethasone
RMPT	Revlimid, Melphalan, Prednisone, Thalidomide
RRMM	Relapsed/Refractory Multiple Myeloma
RVd	Revlimid, Velcade, low-dose Dexamethasone
RVD	Revlimid, Velcade, Dexamethasone
RWD	Real world data
sCR	Stringent Complete Response (CR plus normal free light chain ratio and no clonal plasma cells)
SCT	Stem Cell Transplant
SD	Stable Disease
SINE	Selective Inhibitor of Nuclear Export (Selinexor)
SMM	Smoldering Multiple Myeloma
SPEP	Serum Protein Electrophoresis
SPM	Second Primary Malignancy
SQ	Subcutaneous (sometimes abbreviated SC)
SRE	Skeletal Related Event
ß2M	Beta-2 Microglobulin
TCR	T-cell Receptor
TMI	Too Much Information
TTP	Time to Progression
UHiR	Ultra-High Risk
UPEP	Urine Protein Electrophoresis
VCF	Vertebral Compression Fracture
VDT-PACE	Velcade, Dexamethasone, Thalidomide, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide
VEGF	Vascular Endothelial Growth Factor
VGPR	Very Good Partial Response
VMP-Dara	Velcade, Melphalan, Prednisone plus Daratumumab (RRMM)
VRd	Velcade, Revlimid, Low-Dose Dexamethasone
VTD	Velcade, Thalidomide, Dexamethasone
VTD-Dara	Velcade, Thalidomide, Dexamethasone, Daratumumab
WBC	White Blood Cells
WBLD CT	Whole-Body Low-Dose CT
WBLD MRI	Whole-Body Low-Dose MRI
ZOL	Zoledronic acid (Zometa)